Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

An investigational treatment, used in combination with another cancer medication, took an important step forward after ...

After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted the biologics license ...

Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected April 2026.

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received ...

Nivolumab significantly improved median RFS and DMFS compared to ipilimumab in resected stage IIIB to IIIC or IV melanoma patients. The study suggested potential benefits of morning dosing, with ...

Overall survival was significantly better with the combination therapy, achieving 23.1 months versus 19.6 months with PHP alone. Combination therapy of percutaneous hepatic perfusion with immune ...